Recommended Articles
Fundraising

Nouscom Raises €120M ($135M) Series D to Intercept Cancer Before It Starts

By Angeled · October 19, 2026 · Fundraising
Nouscom Raises €120M ($135M) Series D to Intercept Cancer Before It Starts
Nouscom Raises €120M ($135M) Series D to Intercept Cancer Before It Starts

Nouscom, a clinical-stage Swiss biotech, has closed an oversubscribed €120 million ($135 million) Series D to advance its lead asset NOUS-209 into a registration-enabling clinical trial for cancer interception in Lynch syndrome carriers. The round was announced on October 19, 2026.

The syndicate

The round was co-led by M Ventures (the corporate venture arm of Germany's Merck KGaA) and Revelation Partners. New investors include Angelini Industries, the European Investment Bank, and Neva SGR (Intesa Sanpaolo's venture arm). All existing investors participated — a notable show of conviction — including 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, CDP Venture Capital, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, and XGEN Ventures.

What is cancer interception?

Treatment stops cancer. Prevention tries to avoid it. Interception sits between: using medicine to stop precancerous or early-stage disease from becoming full-blown cancer in people known to be at high risk. NOUS-209 is an off-the-shelf neoantigen-based immunotherapy — essentially a therapeutic vaccine — targeting mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) tumors.

The science: Lynch syndrome carriers have inherited mutations in DNA repair genes, which causes characteristic frameshift mutations in tumors that produce abnormal peptide fragments (frameshift peptide neoantigens) found on cancer cells but absent in healthy tissue. NOUS-209 uses two viral vectors to deliver 209 of these shared neoantigens, training the immune system to recognize and destroy rogue cells before they develop into cancer.

The unmet need: Lynch syndrome

Lynch syndrome is an inherited condition that raises lifetime cancer risk to around 80%, with colorectal cancers occurring in up to 50% of carriers (versus ~2% of the general population) plus elevated risks of endometrial, urothelial, ovarian, gastrointestinal, brain, and some skin cancers. An estimated 1.1–1.2 million people in the US carry the mutations — but as many as 95% don't know they have it, because genetic testing is rarely done without a family history of early-onset cancer.

As CEO Marina Udier put it: "Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery."

The clinical data

NOUS-209 has already shown positive safety and immunogenicity in a Phase Ib/II trial in Lynch syndrome carriers, and long-term follow-up data — carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer as determined by colonoscopy, after one to two years — will be presented at the ESMO Congress in Madrid (October 23–27, 2026) by principal investigator Eduardo Vilar-Sanchez of MD Anderson Cancer Center. The FDA has granted Fast Track designation for the Lynch syndrome indication.

Separately, NOUS-209 is in Phase II trials for advanced dMMR/MSI-H metastatic colorectal cancer, both as a front-line treatment and in combination with Merck & Co.'s Keytruda in patients whose disease is refractory to anti-PD-1 therapy.

The Basel-based company was founded in 2015.

Why it matters for founders and investors

For founders: Nouscom demonstrates that a genetically defined population can be a viable go-to-market for immunotherapy — not just a precision-medicine segmentation tactic, but the product's core strategy. In biotech, "prevent" has historically been a weak commercial pitch because of long, expensive trials; "intercept" in a high-risk, identifiable cohort is a fundable middle path.

For investors: this is a bet on a new category — off-the-shelf cancer vaccines — with a built-in proof-of-concept design: Lynch syndrome carriers give clean clinical endpoints (adenoma-free rates) years before a traditional prevention trial would read out. The key watchpoint is the ESMO long-term data: durable adenoma prevention is what justifies the registration-enabling trial design.

Angeled.com connects founders building in biotech with investors.


Sources: Nouscom company announcement (Oct 19, 2026); Dow Jones Newswires via Morningstar; FirstWord Pharma; Pharmaphorum; European Biotechnology. Clinical claims are company-reported and pending peer-reviewed presentation.

Read Next